Why the study?
Does thrombolytic therapy extend home time in patients with ischemic stroke?
Does thrombolytic therapy extend home time in patients with ischemic stroke?
Home time is a responsive complementary outcome measure for acute stroke trials that should be adjusted for key baseline covariates.
Answers are grounded in this paper and cite their sources.
Observational home time gains with thrombolysis support its use as outcome; leaves open causal effects in randomized stroke trials.
HT is a responsive measure for use in multinational acute stroke trials. Its inclusion as a complementary outcome is reasonable. We propose treatment effects are adjusted for age, baseline National Institutes of Health Stroke Scale, side of stroke lesion, country of enrollment, and the presence of diabetes.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: